SCHEMBL19630971

SCHEMBL19630971

CNC(=O)NS(=O)(=O)c1ccc2c(c1)CCC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
NLRP3 Q96P20 3/20 0.51
ALDH1A1 P00352 2/20 0.51
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA7 P43166 1/20 0.50
CA14 Q9ULX7 1/20 0.50
DPP4 P27487 1/20 0.50
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
POLB P06746 1/20 0.48
CA9 Q16790 1/20 0.48
THRB P10828 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PTGES2 Q9H7Z7 1/20 0.46
BRD1 O95696 1/20 0.45
BRPF1 P55201 1/20 0.45
PKM P14618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19627388 0.85 KDM4E (0.51) KDM4ETDP1NLRP3ALDH1A1CA12
SCHEMBL19630913 0.84 TDP1 (0.56) KDM4ETDP1NLRP3ALDH1A1CA12
SCHEMBL19630993 0.81 KDM4E (0.50) KDM4ETDP1NLRP3ALDH1A1CA12
SCHEMBL15865553 0.81 RAB9A (0.67) NLRP3ALDH1A1CA12CA1CA2
SCHEMBL19631062 0.81 KDM4E (0.56) KDM4ETDP1NLRP3ALDH1A1CA12
SCHEMBL19627395 0.81 KDM4E (0.52) KDM4ETDP1NLRP3ALDH1A1CA12
SCHEMBL19627414 0.81 ALDH1A1 (0.55) KDM4ETDP1NLRP3ALDH1A1CA12
SCHEMBL10154039 0.80 PNMT (0.64) KDM4ETDP1ALDH1A1CA12CA1
SCHEMBL18029637 0.80 NLRP3 (0.74) NLRP3
SCHEMBL2003399 0.80 FBP1 (0.58) KDM4ETDP1ALDH1A1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334894-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-11-23 US disclosed
US-20170333399-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334894-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof SLC10A1, FXR1, NR1H4 KDM4E 4418/4885TDP1 3945/4885NLRP3 1396/4885
US-20170333399-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof SLC10A1, FXR1, SLC10A2 KDM4E 4467/4885TDP1 3899/4885NLRP3 1255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.